FDA approves combination treatment for advanced melanoma
July 30th 2020The U.S. Food and Drug Administration has approved atezolizumab plus cobimetinib and vemurafenib for treatment of BRAF V600 mutation-positive advanced melanoma. Studies show the combination treatment prolonged patients’ lives by 15 months without disease worsening.
FDA approves plaque psoriasis topical
July 23rd 2020The U.S. Food and Drug Administration has approved Wynzora Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%, MC2 Therapeutics) for adult with plaque psoriasis. Wynzora is equipped with the MC2 Therapeutics’ patented PAD Technology and is currently under review in the EU.
The Cutaneous Connection: Episode 3- Climate Change and Skin Diseases
July 23rd 2020This episode discusses a recent survey conducted by the International Society of Dermatology’s Climate Change Committee involving climate change and its effect on skin diseases throughout the world with one of its committee members, Sarah Coates, M.D.
FDA approves guselkumab for psoriatic arthritis
July 16th 2020Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) following positive phase 3 results from two trials investigating the safety and efficacy of the drug.